Abstract
Epiroprim (EPM; Ro 11-8958) is a new selective inhibitor of microbial dihydrofolate reductase. EPM displayed excellent activity against staphylococci, enterococci, pneumococci, and streptococci which was considerably better than that of trimethoprim (TMP). EPM was also active against TMP-resistant strains, although the MICs were still relatively high. Its combination with dapsone (DDS) was synergistic and showed as in vitro activity superior to that of the TMP combination with sulfamethoxazole (SMZ). The EPM-DDS (ratio, 1:19) combination inhibited more than 90% of all important gram-positive pathogens at a concentration of 2 + 38 micrograms/ml. Only a few highly TMP-resistant staphylococci and enterococci were not inhibited. EPM was also more active than TMP against Moraxella catarrhalis, Neisseria meningitidis, and Bacteroides spp., but it was less active than TMP against all other gram-negative bacteria tested. Atypical mycobacteria were poorly susceptible to EPM, but the combination with DDS was synergistic and active at concentrations most probably achievable in biological fluids (MICs from 0.25 +/- 4.75 to 4 + 76 micrograms/ml). EPM and the EPM-DDS combination were also highly active against experimental staphylococcal infections in a mouse septicemia model. The combination EPM-DDS has previously been shown to exhibit activity in Pneumocystis carinii and Toxoplasma models and, as shown in the present study, also shows good activity against a broad range of bacteria including many strains resistant to TMP and TMP-SMZ.
Full Text
The Full Text of this article is available as a PDF (271.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Angehrn P., Hohl P., Hubschwerlen C., Page M., Then R. Antibacterial properties of Ro 40-6890, a broad-spectrum cephalosporin, and its novel orally absorbable ester, Ro 41-3399. Antimicrob Agents Chemother. 1992 Dec;36(12):2825–2834. doi: 10.1128/aac.36.12.2825. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chang H. R., Arsenijevic D., Comte R., Polak A., Then R. L., Pechère J. C. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803–1807. doi: 10.1128/aac.38.8.1803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jorde U. P., Horowitz H. W., Wormser G. P. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS. 1993 Mar;7(3):355–359. doi: 10.1097/00002030-199303000-00008. [DOI] [PubMed] [Google Scholar]
- Lambertus M. W., Kwok R. Y., Mulligan M. E. In vitro susceptibilities of oxacillin-resistant Staphylococcus aureus to dapsone and sulfamethoxazole alone and in combination with trimethoprim. Antimicrob Agents Chemother. 1990 Jul;34(7):1453–1455. doi: 10.1128/aac.34.7.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mehlhorn H., Dankert W., Hartman P. G., Then R. L. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol Res. 1995;81(4):296–301. doi: 10.1007/BF00931533. [DOI] [PubMed] [Google Scholar]
- Wallace R. J., Jr, Nash D. R., Steele L. C., Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol. 1986 Dec;24(6):976–981. doi: 10.1128/jcm.24.6.976-981.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walzer P. D., Foy J., Steele P., White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436–1443. doi: 10.1128/aac.37.7.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]